OncoMatch/Clinical Trials/NCT05183854
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
Is NCT05183854 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pneumococcal 20-valent Conjugate Vaccine and Pneumococcal Polyvalent Vaccine for chronic lymphocytic leukemia.
Treatment: Pneumococcal 20-valent Conjugate Vaccine · Pneumococcal Polyvalent Vaccine — This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect against bacteria that cause pneumococcal disease. Giving these vaccinations as series may make a stronger immune response and prevent against pneumococcal infections in patients with chronic lymphocytic leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Prior therapy
Must have received: BCL2 inhibitor (venetoclax) — VENETOCLAX-TREATMENT COHORT
Subjects must have received venetoclax (any dose) for at least 12 months with the last dose =< 12 months prior to registration.
Cannot have received: any therapy for CLL
Subjects must not have received prior therapy for CLL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute/University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify